Curated dataset · n=61 verified deals · Not live market data · Scores are descriptive, not forecasts.
You are here

Deals — Network graph, deal flow, valuation matrix, and acquirer landscape.

BioReference Health (clinical, women's health, urology and 4Kscore assets)
→
LabCorp

Asset Acquisition · Cash plus earnout · LH · announced Oct 15, 2026

View in network
  1. Announced

    Oct 15, 2026

Economics

Cash plus earnout

$722M cash at closing per OPKO 8-K Item 1.01, subject to upward or downward adjustment based on Business revenues at closing; up to $150M additional earnout (total potential $872M). Select-asset purchase (Asset Purchase Agreement dated Oct 14, 2026), not a whole-company acquisition. Pending: subject to HSR clearance; outside date Apr 14, 2027; $28.88M Buyer termination fee on specified regulatory failure. No closedDate until a completion filing or release.

Target

BioReference Health (clinical, women's health, urology and 4Kscore assets)

Diagnostics · Diagnostic / genomic

HQ Elmwood Park, NJ

Select assets of OPKO Health subsidiary BioReference Health under agreement to Labcorp in 2026: laboratory testing businesses focused on clinical and women's health testing, urology and corrections, over 80 patient service centers and the proprietary 4Kscore prostate cancer test; follows BioReference's 2024 sale of clinical diagnostics and reproductive and women's health assets outside NY/NJ to Labcorp (c152)

  • SEC EDGAR - OPKO Health 8-K Item 1.01 (Oct 15, 2026; Asset Purchase Agreement dated Oct 14, 2026) https://www.sec.gov/Archives/edgar/data/944809/000119312526422877/opk-20261014.htm
  • Labcorp press release via PR Newswire (Oct 15, 2026) https://ir.labcorp.com/news-releases/news-release-details/labcorp-enters-agreement-opko-health-acquire-select-assets
  • Labcorp press release via PR Newswire (Mar 28, 2024; About BioReference Health: "Headquartered in Elmwood Park, New Jersey") https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-acquisition-select-assets-bioreference-healths

Acquirer

LabCorp (LH)

Diagnostics

HQ Burlington, NC

Why this buyer

Curated copy from the verified dataset — not an 8-K LLM summary

Labcorp acquires BioReference Health's laboratory testing businesses focused on clinical and women's health testing services, urology, corrections and certain operational assets, including over 80 additional patient service centers, plus the proprietary 4Kscore Test

Evidence ladder

Dual-source corroborationValue disclosed
  1. Primary (regulatory / filing)

    SEC EDGAR 8-K Item 1.01 (OPKO Health, Oct 15, 2026) https://www.sec.gov/Archives/edgar/data/944809/000119312526422877/opk-20261014.htm

    Open source
  2. Secondary (press / IR)

    Labcorp press release (Oct 15, 2026) https://ir.labcorp.com/news-releases/news-release-details/labcorp-enters-agreement-opko-health-acquire-select-assets

    Open source
  3. Tertiary (trade / analyst)

    CLP Magazine coverage (Oct 15, 2026) https://clpmag.com/lab-management/company-news/labcorp-acquires-bioreference-health-assets-4kscore-test/

    Open source

Limitations

  • $722M cash at closing per OPKO 8-K Item 1.01, subject to upward or downward adjustment based on Business revenues at closing; up to $150M additional earnout (total potential $872M). Select-asset purchase (Asset Purchase Agreement dated Oct 14, 2026), not a whole-company acquisition. Pending: subject to HSR clearance; outside date Apr 14, 2027; $28.88M Buyer termination fee on specified regulatory failure. No closedDate until a completion filing or release.

Valuation peers · Diagnostics

Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer, until you sort.

Why included
BioReference Health (clinical diagnostics and reproductive & women's health, outside NY/NJ)LabCorpMar 28, 2024same evidence class · same acquirer

Same-sector adjacency — not valuation peers

These deals share the sector tag and window but sit outside the 0.25×–4× value band. The dataset keeps them for clinical adjacency, not as price comps.

Vs this deal
Invitae Reproductive HealthNateraJan 22, 2024

Other verified deals by LabCorp

Acquirer program history not already listed as a valuation peer or adjacency row.

Sector
Ovia HealthLabCorpAug 12, 2021UndisclosedMaternal Health
SequenomLabCorpJul 27, 2016Diagnostics

Patient empowerment context

Patient empowerment baseline (HLTH 2022)

No curated mapping — BioReference Health (clinical, women's health, urology and 4Kscore assets) (Diagnostics). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.

Research workspace (includes heuristic crosswalk) →

Related verified workspaces

Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.

Curated verified dataset v11 · updated 2026-10-19 · 3 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.